SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 142,911.53 |
| Enterprise Value ($M) | 191,482.53 |
| Book Value ($M) | 6,207.00 |
| Book Value / Share | 11.54 |
| Price / Book | 23.02 |
| NCAV ($M) | -56,231.00 |
| NCAV / Share | -104.58 |
| Price / NCAV | -2.54 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.09 |
| Return on Assets (ROA) | 0.06 |
| Return on Equity (ROE) | 1.18 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.88 |
| Current Ratio | 1.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 26,929.00 |
| Assets | 89,367.00 |
| Liabilities | 83,160.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 33,424.00 |
| Operating Income | 10,094.00 |
| Net Income | 4,090.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 11,490.00 |
| Cash from Investing | -1,046.00 |
| Cash from Financing | -9,415.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 7.60 | -14.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 813,511 | 2,837,339 | 28.67 | |
| 900,404 | 2,957,215 | 30.45 | |
| 580,740 | 1,786,656 | 32.50 | |
| 898,649 | 2,647,056 | 33.95 | |
| 705,142 | 2,167,444 | 32.53 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALLO – Allogene Therapeutics, Inc. | ALNY – Alnylam Pharmaceuticals, Inc. |
| ALXO – ALX Oncology Holdings Inc. | AMLX – Amylyx Pharmaceuticals, Inc. |
| AMPH – Amphastar Pharmaceuticals, Inc. |